Predictive Value of Preoperative Serum AFP, CEA, and CA19-9 Levels in Patients with Single Small Hepatocellular Carcinoma: Retrospective Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;362(9822):1245–1255. doi:10.1016/S0140-6736(11)61347-0
   Web of Science ®Google Scholar
• Bruix J, Sherman M; American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi:10.1002/hep.24199
   PubMed Web of Science ®Google Scholar
• Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol. 2010;25(3):439–452. doi:10.1111/j.1440-1746.2009.06207.x
   PubMed Web of Science ®Google Scholar
• Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology. 2001;34(4):707–713. doi:10.1053/jhep.2001.27950
   PubMed Web of Science ®Google Scholar
• Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257–261. doi:10.1038/s41586-019-0987-8
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. doi:10.1053/j.gastro.2015.12.041
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol. 2016;64(3):594–600. doi:10.1016/j.jhep.2015.10.015
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235(3):373–382. doi:10.1097/00000658-200203000-00009
   PubMed Web of Science ®Google Scholar
• Qin C, Gao Y, Li J, Huang C, He S. Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma. Oncol Lett. 2021;21(6):487. doi:10.3892/ol.2021.12748
   PubMed Web of Science ®Google Scholar
• Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi:10.1111/liv.14223
   PubMed Web of Science ®Google Scholar
• Sachan A, Saluja SS, Nekarakanti PK, et al. Raised CA19-9 and CEA have prognostic relevance in gallbladder carcinoma. BMC Cancer. 2020;20(1):826. doi:10.1186/s12885-020-07334-x
   PubMed Web of Science ®Google Scholar
• Kim M, Kim H, Han Y, et al. Prognostic Value of Carcinoembryonic Antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in gallbladder cancer; 65 IU/mL of CA 19-9 is the new cut-off value for prognosis. Cancers. 2021;13(5):1089.
   PubMed Web of Science ®Google Scholar
• Edoo MIA, Chutturghoon VK, Wusu-Ansah GK, et al. Serum biomarkers AFP, CEA and CA19-9 combined detection for early diagnosis of hepatocellular carcinoma. Iran J Public Health. 2019;48(2):314–322.
   PubMed Web of Science ®Google Scholar
• Wang YF, Feng FL, Zhao XH, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol. 2014;20(14):4085–4092. doi:10.3748/wjg.v20.i14.4085
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020;146(10):2439–2446. doi:10.1007/s00432-020-03331-6
   PubMed Web of Science ®Google Scholar
• Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. doi:10.1038/s41598-017-12834-1
   PubMed Web of Science ®Google Scholar
• Yang W, Luo Y, Hu S, Li Y, Liu Q. Value of combined detection of serum carcino-embryonic antigen, carbohydrate antigen 19-9 and cyclooxygenase-2 in the diagnosis of colorectal cancer. Oncol Lett. 2018;16(2):1551–1556. doi:10.3892/ol.2018.8792
   PubMed Web of Science ®Google Scholar
• Yoshikawa M, Morine Y, Ikemoto T, et al. Elevated preoperative serum CEA level is associated with poor prognosis in patients with hepatocellular carcinoma through the epithelial-mesenchymal transition. Anticancer Res. 2017;37(3):1169–1175.
   PubMed Web of Science ®Google Scholar
• Qi F, Zhou A, Yan L, et al. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma. J Clin Lab Anal. 2020;34(5):e23158. doi:10.1002/jcla.23158
   PubMed Web of Science ®Google Scholar
• Hou GM, Liu HL, Wu H, Zeng Y. Prediction of prognosis for cHCC-CC patients after surgery: comparison of tumor marker score based on AFP, CEA, CA19-9, and other clinical stages. Ann Surg Oncol. 2021;28(12):7647–7660. doi:10.1245/s10434-021-09949-1
   PubMed Web of Science ®Google Scholar
• Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci. 2011;56(8):2491–2496. doi:10.1007/s10620-011-1709-8
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang Y, Dong X, et al. Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma. Biosci Trends. 2022;15(6):397–405. doi:10.5582/bst.2021.01517
   PubMed Web of Science ®Google Scholar
• Liu W, Li X, Zheng W, Yao R, Zheng J. Preoperative evaluation of the degree of liver fibrosis based on matter-element analysis using serological indicators in patients with hepatocellular carcinoma. Biosci Trends. 2019;13(1):70–76. doi:10.5582/bst.2018.01311
   PubMed Web of Science ®Google Scholar
• Tsuji M, Kashihara T, Terada N, Mori H. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int. 1999;49(4):310–317. doi:10.1046/j.1440-1827.1999.00865.x
   PubMed Web of Science ®Google Scholar
• Wakizaka K, Yokoo H, Kamiyama T, et al. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol. 2019;34(6):1074–1080. doi:10.1111/jgh.14547
   PubMed Web of Science ®Google Scholar
• Kim KH, Lee SG, Park EH, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16(3):623–629. doi:10.1245/s10434-008-0278-3
   PubMed Web of Science ®Google Scholar
• Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371:m3544. doi:10.1136/bmj.m3544
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M; Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236. doi:10.1002/hep.20933
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Tsuji K, et al. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis. Liver Cancer. 2019;8(2):121–129.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Michitaka K, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31(5):1031–1036. doi:10.1111/jgh.13250
   PubMed Web of Science ®Google Scholar
• Wang XH, Long LH, Cui Y, et al. MRI-based radiomics model for preoperative prediction of 5-year survival in patients with hepatocellular carcinoma. Br J Cancer. 2020;122(7):978–985. doi:10.1038/s41416-019-0706-0
   PubMed Web of Science ®Google Scholar
• Chen T, Dai X, Dai J, et al. AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway. Cell Death Dis. 2020;11(10):822. doi:10.1038/s41419-020-03030-7
   PubMed Web of Science ®Google Scholar
• Sauzay C, Petit A, Bourgeois AM, et al. Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39–44. doi:10.1016/j.cca.2016.10.006
   PubMed Web of Science ®Google Scholar
• Hsu CC, Goyal A, Iuga A, et al. Elevated CA19-9 is associated with increased mortality in a prospective cohort of hepatocellular carcinoma Patients. Clin Transl Gastroenterol. 2015;6(2):e74. doi:10.1038/ctg.2014.22
   PubMed Web of Science ®Google Scholar
• Zhao H, Hua Y, Lu Z, et al. Prognostic value and preoperative predictors of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm without macrovascular invasion. Oncotarget. 2017;8(37):61203–61214. doi:10.18632/oncotarget.18049
   PubMedGoogle Scholar
• Oishi K, Itamoto T, Amano H, et al. Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol. 2007;95(4):311–316. doi:10.1002/jso.20661
   PubMed Web of Science ®Google Scholar
• Pan J, Chen S, Tian G, Jiang T. Preoperative albumin-bilirubin grade with prognostic nutritional index predicts the outcome of patients with early-stage hepatocellular carcinoma after percutaneous radiofrequency ablation. Front Med. 2020;7:584871. doi:10.3389/fmed.2020.584871
   Web of Science ®Google Scholar
• Yanagaki M, Haruki K, Yasuda J, et al. The significance of the rapid turnover protein score as a predictor of the long-term outcomes in hepatocellular carcinoma after hepatic resection. Ann Surg Oncol. 2021;28(13):8130–8139. doi:10.1245/s10434-021-10704-9
   PubMed Web of Science ®Google Scholar
• Yang J, Bao Y, Chen W, Duan Y, Sun D. Nomogram based on systemic immune inflammation index and prognostic nutrition index predicts recurrence of hepatocellular carcinoma after surgery. Front Oncol. 2020;10:551668. doi:10.3389/fonc.2020.551668
   PubMed Web of Science ®Google Scholar
• Shen Y, Wang H, Li W, Chen J. Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA. J Clin Lab Anal. 2019;33(9):e22999. doi:10.1002/jcla.22999
   PubMed Web of Science ®Google Scholar
• Yang YT, Jiang JH, Yang HJ, Wu ZJ, Xiao ZM, Xiang BD. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival compared to established biomarkers in HCC patients undergoing liver resection. Sci Rep. 2018;8(1):2535. doi:10.1038/s41598-018-20199-2
   PubMed Web of Science ®Google Scholar
• He C, Zhang Y, Cai Z, Lin X. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. Cancer Manag Res. 2019;11:1391–1400. doi:10.2147/CMAR.S190545
   PubMed Web of Science ®Google Scholar
• Minagawa M, Mise Y, Omichi K, et al. Anatomic resection for hepatocellular carcinoma: prognostic impact assessed from recurrence treatment. Ann Surg Oncol. 2022;29(2):913–921. doi:10.1245/s10434-021-10380-9
   PubMed Web of Science ®Google Scholar
• Tanaka K, Shimada H, Matsumoto C, et al. Anatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma. Surgery. 2008;143(5):607–615. doi:10.1016/j.surg.2008.01.006
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Cescon M, Ercolani G, Bigonzi E, Torzilli G, Pinna AD. A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Ann Surg Oncol. 2012;19(12):3697–3705. doi:10.1245/s10434-012-2450-z
   PubMed Web of Science ®Google Scholar
• Eguchi S, Kanematsu T, Arii S, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery. 2008;143(4):469–475. doi:10.1016/j.surg.2007.12.003
   PubMed Web of Science ®Google Scholar
• Wakai T, Shirai Y, Sakata J, et al. Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol. 2007;14(4):1356–1365. doi:10.1245/s10434-006-9318-z
   PubMed Web of Science ®Google Scholar
• Ishii M, Mizuguchi T, Kawamoto M, et al. Propensity score analysis demonstrated the prognostic advantage of anatomical liver resection in hepatocellular carcinoma. World J Gastroenterol. 2014;20(12):3335–3342. doi:10.3748/wjg.v20.i12.3335
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Qiao GL, Cescon M, et al. Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma. Surgery. 2014;155(3):512–521. doi:10.1016/j.surg.2013.10.009
   PubMed Web of Science ®Google Scholar
• Hirokawa F, Kubo S, Nagano H, et al. Do patients with small solitary hepatocellular carcinomas without macroscopically vascular invasion require anatomic resection? Propensity score analysis. Surgery. 2015;157(1):27–36. doi:10.1016/j.surg.2014.06.080
   PubMed Web of Science ®Google Scholar
• Okamura Y, Ito T, Sugiura T, Mori K, Uesaka K. Anatomic versus nonanatomic hepatectomy for a solitary hepatocellular carcinoma: a case-controlled study with propensity score matching. J Gastrointest Surg. 2014;18(11):1994–2002. doi:10.1007/s11605-014-2646-6
   PubMed Web of Science ®Google Scholar
• Marubashi S, Gotoh K, Akita H, et al. Anatomical versus non-anatomical resection for hepatocellular carcinoma. Br J Surg. 2015;102(7):776–784. doi:10.1002/bjs.9815
   PubMed Web of Science ®Google Scholar